Fig. 1From: Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphomaa Comparison of clinical characteristics of patients between Hodgkin lymphoma and primary mediastinal large B-cell lymphoma at the time of enrollment; b One case of Hodgkin lymphoma achieved complete response; c One patient with Hodgkin lymphoma achieving stable disease after the second cycle also showed improved disease statusBack to article page